Previous 10 | Next 10 |
Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That's because the company had some very encouraging news to impart about its key pipeline drug. DBV is developing a patch treatment for peanut all...
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
Cyren (CYRN) +39% on €10M sale of secure email gateway unit. Redbox Entertainment (RDBX) +25%. DBV Technologies (DBVT) +19% phase 3 trial for peanut allergy treatment in toddlers meets main goal. Brenmiller Energy (BNRG) +16%. Energy Focus (EFOI) +15%. Aldeyra Thera...
3 Penny Stocks That Climbed in After Hours Trading After a mostly bullish day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have to consider the main factors that are at play in the stock market. This includes rising inflation, and more impo...
U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut...
Gainers: DBV Technologies (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...
Montrouge, France, June 7, 2022 DBV Technologies Announce s Positive Topline Results from Phase 3 EPITOPE T rial of Viaskin Peanut in Peanut - Allerg ic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE E...
Montrouge, France, May 12, 2022 DBV Technologies Announces Results of I ts 2022 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed Re solutions DBV Technologies (Euronext: DBV – ISI...
Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $ 15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “C...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...